-+ 0.00%
-+ 0.00%
-+ 0.00%

Coherus BioSciences Announces Clinical Collaboration With STORM Therapeutics To Evaluate STC-15, METTL3 Inhibitor, In Combination With LOQTORZI, Next-Gen PD-1 Inhibitor, In Phase 1b/2 Study For NSCLC, HNSCC, Melanoma And Endometrial Cancer Treatment

Benzinga·05/27/2025 12:36:21
Listen to the news

Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. ("STORM") to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma and endometrial cancer.